| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/10-1/50 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | HA-1; HMHA1; HLA-HA1 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human ARHGAP45 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于ARHGAP45抗体的3篇参考文献示例(文献信息为虚构，仅供格式参考)：
1. **文献名称**：*ARHGAP45 regulates T-cell activation through cytoskeletal remodeling*
**作者**：Li X, et al.
**摘要**：研究利用ARHGAP45抗体进行Western blot和免疫荧光，发现ARHGAP45通过抑制RhoA活性调控T细胞活化过程中的肌动蛋白重组。
2. **文献名称**：*Role of ARHGAP45 in neuronal migration: Insights from antibody-based knockdown assays*
**作者**：Saito M, et al.
**摘要**：通过ARHGAP45抗体阻断实验，证明其在神经元迁移中通过调控细胞极性相关信号通路发挥作用。
3. **文献名称**：*ARHGAP45 expression correlates with metastatic potential in breast cancer*
**作者**：Chen R, et al.
**摘要**：使用ARHGAP45抗体进行免疫组化分析，发现其高表达与乳腺癌细胞侵袭性增强相关，提示其作为预后标志物的潜力。
(注：以上文献为示例，实际引用需查询真实数据库如PubMed。)
The ARHGAP45 antibody is a crucial tool for studying the ARHGAP45 protein, a member of the Rho GTPase-activating protein (RhoGAP) family. ARHGAP45 negatively regulates Rho GTPases, such as RhoA, Rac1. and Cdc42. by accelerating their GTP hydrolysis, thereby modulating cytoskeletal dynamics, cell migration, and immune cell functions. It contains a conserved RhoGAP domain and is implicated in immune regulation, cancer progression, and neurological processes. Studies suggest its role in T-cell activation, neutrophil migration, and platelet function, highlighting its importance in inflammatory and autoimmune diseases.
ARHGAP45 antibodies are widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to detect protein expression, localization, and interactions. These antibodies are often raised in rabbits or mice using immunogenic peptide sequences specific to human ARHGAP45. with cross-reactivity validated in model organisms like mice and rats. Commercial antibodies typically undergo rigorous validation using knockout controls or siRNA-mediated knockdown to ensure specificity. Researchers rely on them to explore ARHGAP45's regulatory mechanisms in pathologies such as leukemia, glioblastoma, and rheumatoid arthritis. Additionally, some antibodies distinguish between splice variants or post-translational modifications, aiding functional studies. As ARHGAP45 gains attention in drug discovery, its antibodies remain pivotal for unraveling its therapeutic potential.
×
